全身β受体阻滞剂与新生血管性年龄相关性黄斑变性进展风险
基于美国大型全国性保险理赔数据库2000至2014年的回顾性队列研究,比较口服β受体阻滞剂(BB)与其他降压药患者发生新生血管性年龄相关性黄斑变性(nAMD)的风险。结果显示BB使用者90天和180天nAMD风险低于钙通道阻滞剂(CCB)和利尿剂使用者,但365天时无显著差异;未发现BB增加nAMD风险。
要点
- BB使用者90天和180天nAMD风险低于CCB使用者(HR 0.67-0.71,P<0.01)。
- BB使用者90天和180天nAMD风险低于利尿剂使用者(HR 0.55-0.62,P<0.01)。
- 倾向评分匹配后BB使用者90天和180天nAMD风险仍低于CCB使用者(HR 0.70-0.76,P<0.049),365天无显著差异(HR 0.88,P=0.30)。
核心结论
- 未发现BB使用相对于其他降压药增加nAMD风险。
研究设计与样本
- 回顾性队列研究,使用美国大型全国性保险理赔行政数据库2000至2014年数据。
- 纳入初始使用BB、CCB、ACEI/ARB或利尿剂的无渗出性AMD患者,排除指数日期前参保不足2年、有nAMD病史或诊断、或接受可能与nAMD混淆的眼病治疗者。
- 主要分析比较BB与CCB,次要分析比较BB与其他药物类别,另以1:1倾向评分匹配进行敏感性分析。
- 采用Cox比例风险回归估计BB使用者在90、180和365天发生nAMD的风险比。
主要发现
- 控制协变量后,BB患者90天和180天nAMD风险低于CCB患者(HR 0.67-0.71,P<0.01)。
- BB患者90天和180天nAMD风险低于利尿剂患者(HR 0.55-0.62,P<0.01)。
- BB与ACEI/ARB在所有时间点及BB与CCB和利尿剂在365天时nAMD关联无显著降低(HR 0.73-0.85,P>0.06)。
- 倾向评分匹配敏感性分析显示BB患者90天和180天发生nAMD可能性显著低于CCB患者(HR 0.70-0.76,P<0.049),365天无显著差异(HR 0.88,P=0.30)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To determine whether oral beta-blockers (BBs) are associated with the development of neovascular age-related macular degeneration (nAMD). METHODS: Retrospective cohort study of patients from 2000 to 2014 using data from a large national U.S. insurer's administrative medical claims database. Patients with nonexudative AMD who initiated (index date) BB, a calcium channel blocker (CCB), an angiotensin-converting enzyme/angiotensin receptor blocker, or a diuretic. Patients were excluded for <2 years in the plan before the index date, any history of nAMD or diagnosis, or treatment for an ocular disease that could be confused with nAMD. Hazard of developing of nAMD was the main outcome measure. Primary analysis compared BB with CCB patients with BB versus the other classes as secondary analyses. In addition, a sensitivity analysis was performed between BB and CCB cohorts using 1:1 propensity score matching. Cox proportional hazard regression was performed to estimate the hazard ratio (HR) of developing nAMD at 90, 180, and 365 days for BB. Covariates of interest included demographic information, year of index date, number of antihypertensive medications, and other comorbid systemic conditions. RESULTS: Eighteen thousand seven hundred and fifty-four BB patients and 12,784 CCB patients met criteria for inclusion. After controlling for covariates, patients on BB had a lower hazard for nAMD at both 90 and 180 days than patients on CCB (HRs: 0.67-0.71; P < 0.01 for both) and diuretics (HRs: 0.55-0.62; P < 0.01). Patients on BB versus angiotensin-converting enzyme/angiotensin receptor blocker at all time points and BB versus CCB and diuretics at 365 days did not have a significantly lower association with nAMD (HR: 0.73-0.85; P > 0.06 for all comparisons). A sensitivity analysis using propensity score matching yielded similar results with patients on BB significantly less likely to develop nAMD at 90 and 180 days (HR: 0.70-0.76; P < 0.049 for both) but not at 365 days (HR: 0.88; P = 0.30) compared with patients on CCB. CONCLUSION: No evidence was found that BB usage increased the hazard for nAMD relative to other antihypertensive medications.
引用
- Kolomeyer AM, Maguire MG, Pan W, et al. SYSTEMIC BETA-BLOCKERS AND RISK OF PROGRESSION TO NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina. 2019. PMID: 29394237. doi:10.1097/IAE.0000000000002059
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。